|
Axonal guidance signaling
|
4.5
|
EPHA7, ARHGEF12,SOS2,PTCH1,ITGA5,ROBO1,WNT2,EFNB2,FZD4,IGF1,EFNB1,GNA13,PRKD3,ADAM9,NRP1
|
|
Role of NANOG in mammalian embryonic stem cell pluripotency
|
3.65
|
SOX2,LIF,FZD4,GAB1,SOS2,BMPR2,WNT2
|
|
HGF signaling
|
3.07
|
ETS1,GAB1,SOS2,MAPK10,ETS2,PRKD3
|
|
Cholecystokinin/gastrin-mediated signaling
|
3.02
|
ITPR2,SOS2,MAPK10,RHOU,GNA13,PRKD3
|
|
Pantothenate and CoA biosynthesis
|
2.93
|
PANK1,ENPP1,ENPP5
|
|
Molecular mechanisms of cancer
|
2.82
|
ARHGEF12,FZD4,GAB1,SOS2,PTCH1,MAPK10,RHOU,BMPR2,HIF1A,GNA13,PRKD3
|
|
Endothelin-1 signaling
|
2.56
|
EDNRB,GAB1,ITPR2,MAPK10,MAPK6,GNA13,PRKD3
|
|
RAR activation
|
2.49
|
TAF4 RARB,IGFBP3,MAPK10,NCOR1,PRKD3,PPARGC1A
|
|
Mouse embryonic stem Cell pluripotency
|
2.37
|
SOX2,LIF,FZD4,SOS2,BMPR2
|
|
Phospholipase C signaling
|
2.35
|
ARHGEF12,ITPR2,SOS2,RHOU,RPS6KA3,ITGA5,GNA13,PRKD3
|
|
IGF-1 signaling
|
2.31
|
CTGF,IGF1,SOS2,IGFBP3,GRB10
|
|
Hepatic fibrosis/hepatic stellate cell activation
|
2.31
|
COL1A2,CTGF,IGF1,EDNRB,FLT1,IGFBP3
|
|
ERK5 signaling
|
2.29
|
LIF,GAB1,RPS6KA3,GNA13
|
|
Glioblastoma multiforme signaling
|
2.17
|
FZD4,IGF1,ITPR2,SOS2,RHOU,WNT2
|
|
Growth hormone signaling
|
2.15
|
IGF1,IGFBP3,RPS6KA3,PRKD3
|
|
GDNF family ligand-receptor interactions
|
2.15
|
GAB1,ITPR2,SOS2,MAPK10
|
|
Renal cell carcinoma signaling
|
2.11
|
ETS1,GAB1,SOS2,HIF1A
|
